Mizuho raised the firm’s price target on Merck to $138 from $130 and keeps a Buy rating on the shares. The analyst sees the company’s current pipeline “having that critical mass where investors can begin to visualize MRK‘s P&L through crucial years.” The firm updated its model for 2024, which now includes six additional late-stage candidates. It calls Merck a top pick for 2024.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on MRK:
- Merck upgraded to Outperform from Market Perform at TD Cowen
- The biopharmaceuticals stocks to own in 2024, according to BofA
- Vaxcyte price target raised to $80 from $72 at Guggenheim
- Cocrystal Pharma price target lowered to $10 from $12 at H.C. Wainwright
- Moderna price target raised to $120 from $110 at BofA